Oxyferriscorbone elevates the total iron content of blood but not brain

Authors

  • D. T. Dexter,

    1. MRC Movement Disorders Research Group, University Department of Neurology and Parkinson's Disease Society Research Centre, Institute of Psychiatry and King's College Hospital Medical School, London, U.K.
    Search for more papers by this author
  • Dr. P. Jenner,

    Corresponding author
    1. MRC Movement Disorders Research Group, University Department of Neurology and Parkinson's Disease Society Research Centre, Institute of Psychiatry and King's College Hospital Medical School, London, U.K.
    • MRC Movement Disorders Research Group, University Department of Neurology and Parkinson's Disease Society Research Centre, Institute of Psychiatry and King's College Hospital Medical School, Denmark Hill, London SE5, U.K.
    Search for more papers by this author
  • Dr. C. D. Marsden

    1. MRC Movement Disorders Research Group, University Department of Neurology and Parkinson's Disease Society Research Centre, Institute of Psychiatry and King's College Hospital Medical School, London, U.K.
    Current affiliation:
    1. University Department of Clinical Neurology, Institute of Neurology, National Hospital, London
    Search for more papers by this author

Abstract

Following the intravenous infusion of oxyferriscorbone into the tail vein of the rat, the blood and brain metal ion content was measured over the following 72 h period. Administration of oxyferriscorbone increased the total iron content of blood for up to 24 h following intravenous infusion. In contrast, there was no increase in the total iron content of the cerebellum or striatum. Overall, there was no change in total zinc or copper content of the blood or brain following oxyferriscorbone administration. The effect of oxyferriscorbone in Parkinson's disease may not be related to any alteration in total iron content of the brain.

Ancillary